Daniel J. Mulder

Daniel J. Mulder

Auto-generated profile, based on publicly available information

Daniel J. Mulder

Gastrointestinal Diseases Research Unit, Faculty of Health Sciences Kingston Ontario K7L 2V7 Queen's University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Cell
Verified
Journal Article
Closed access
YYYikun Yao
Yikun Yao
GKGirak Kim
Girak Kim
SSSamantha Shafer
Samantha Shafer
ZCZuojia Chen
Zuojia Chen
SKSatoshi Kubo
Satoshi Kubo
MLMichael J. Lenardo
Michael J. Lenardo

1 May 2014 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
DMDaniel J. Mulder
Daniel J. Mulder
ANAngela J. Noble
Angela J. Noble
CJChristopher J. Justinich
Christopher J. Justinich
JDJacalyn M. Duffin
Jacalyn M. Duffin
'Inflammatory bowel disease' (IBD) sounds like a straightforward term - a disease of inflammation in the bowel. However, the history of IBD reveals a story of a nefariously complex set of idiopathic conditions. IBD defies definition, in part because its pathophysiology is not completely understood. For the same reason and despite substantial advances in research, IBD also defies cure. At best, IBD can be defined as a disease of disruption - disrupted physiology, microbiology, immunology and genetics. The term 'IBD' is most often used to describe two separate conditions: ulcerative colitis (UC) and Crohn's disease (CD). This paper reviews the history of IBD, considering the ever-evolving understanding of both UC and CD. Beyond its intrinsic interest, the history of IBD exemplifies a pattern that is becoming increasingly familiar in the 21st century - the story of a chronic, incurable disease that defies the best efforts to treat it.

29 March 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LWLin Wang
Lin Wang
DADominik Aschenbrenner
Dominik Aschenbrenner
ZZZhiyang Zeng
Zhiyang Zeng
XCXiya Cao
Xiya Cao
DMDaniel Mayr
Daniel Mayr
AMAleixo M. Muise
Aleixo M. Muise

1 February 2011 in The American Journal of Pathology
Verified
Journal Article
Closed access
DMDaniel J. Mulder
Daniel J. Mulder
APAman Pooni
Aman Pooni
NMNanette Mak
Nanette Mak
DHDavid J. Hurlbut
David J. Hurlbut
SBSameh Basta
Sameh Basta
CJChristopher J. Justinich
Christopher J. Justinich

31 October 2008 in Gut
Verified
Journal Article
Open access
PDF file
DMD J Mulder
D J Mulder
IPI Pacheco
I Pacheco
DHD J Hurlbut
D J Hurlbut
NMN Mak
N Mak
GFG T Furuta
G T Furuta
CJC J Justinich
C J Justinich
Background: Oesophagitis is characterised by basal cell hyperplasia and activated eosinophils, which release mediators including major basic protein (MBP). MBP and its mimetic polyarginine activate the calcium sensing receptor (CaSR) on oesophageal epithelium. Fibroblast growth factor 9 (FGF9) is implicated in epithelial homeostasis and proliferative response to injury, but has not been characterised in the oesophagus. Objective: To characterise FGF9 in oesophageal epithelium and oesophagitis, as the result of MBP activation of the CaSR. Methods: Human oesophageal epithelial cells (HET-1A) were used to compare affects of calcium, polyarginine and MBP-peptide on FGF9. HET-1A were transfected with interfering RNA (siRNACaSR). FGF9, FGF receptors 2 and 3, bone morphogenetic protein (BMP)-2, BMP-4 and noggin mRNA expression were detected by reverse transcriptase polymerase chain reaction. FGF9 was measured from HET-1A and from normal, gastro-oesophageal reflux and eosinophilic oesophagitis (EoE) patient biopsies using ELISA and immunohistochemistry. HET-1A proliferation was studied using bromodeoxyuridine and MTT. Results: FGF9 was secreted by HET-1A cells treated with polyarginine and MBP-peptide, but not calcium. This effect was abrogated by siRNACaSR. FGF9 receptor mRNA was present. HET-1A cells proliferated following rhFGF9, but not MBP-peptide treatment, and rhFGF9 altered transcription of downstream proliferation-related genes (noggin, BMP-2 and BMP-4). FGF9 was increased in biopsies from patients with eosinophilic oesophagitis, which correlated with basal hyperplasia. Conclusion: Eosinophil-released MBP acts on the CaSR to increase FGF9 in oesophageal epithelial cells, leading to proliferation. Increased FGF9 is found in biopsies of EoE patients and may play a role in the pathogenesis of oesophagitis.

1 March 2011 in Mucosal Immunology
Verified
Journal Article
Closed access
PDF file
DMD J Mulder
D J Mulder
CJC J Justinich
C J Justinich